INCLUSION CRITERIA:  Inclusion Criteria for All Participants  Aged >=3 years. Able to provide informed consent or, if younger than 18, be accompanied by a parent(s)/legal guardian(s) who is able to provide informed consent. Willing to allow genetic testing on their collected biological samples.  Additional Inclusion Criteria for Participants with HPV-related Diseases  Has severe, disseminated, recurrent, and treatment-refractory HPV infection, defined as one or more of the following:  In participants without known primary or acquired immunodeficiency:  Multiple skin warts (>=5) recurrent* or refractory to standard-of-care interventions (eg, topical imiquimod, acetylsalicylic acid, cryotherapy, cantharidin, podophyllotoxin, bleomycin, cauterization, cidofovir, fluorouracil). Concomitant skin warts (irrespective to recurrence or treatment response) AND any historical or current clinical and/or histologic or cytologic evidence of mucosal HPV-related diseases (oral, nasal, laryngeal, vaginal, anal, penile, or cervical). Mucosal HPV-related diseases that are recurrent* or refractory to standard-of-care interventions and involve more than one mucosal site (eg, anal condyloma and low-grade squamous intraepithelial lesion on Pap smear; or oral and anal condylomas).  In participants with known primary or acquired immunological defect (including idiopathic CD4 lymphopenia, immunosuppressive treatment, or HIV/AIDS):  --Any skin OR mucosal HPV-related diseases that are recurrent or refractory to standard-of-care intervention.  In any participant:  Recurrent invasive skin or mucosal HPV-related squamous cell carcinoma (HPV-SCC).  Historical or current histologic evidence of invasive HPV-SCC of any mucosal site in subjects with family history of HPV-SCC in 1 or more family members.  The lack of complete response to 2 or more interventions is defined as treatment-refractory disease in the protocol, while the reappearance of a skin or mucosal lesion after complete resolution is defined as recurrence.  Additional Inclusion Criteria for Biological Relatives  -Biological relative of the index participant (with HPV-related diseases) who meets one of the following criteria:  does not have any historical or current clinical and/or histologic or cytologic evidence of skin or mucosal HPV-related diseases, or has historical or current clinical and/or histologic or cytologic evidence of skin or mucosal HPV-related diseases but does not meet the criteria to be enrolled in this study as a participant with HPV-related disease.  EXCLUSION CRITERIA:  Individuals meeting any of the following criteria will be excluded from study participation:  Laboratory abnormalities contraindicating research evaluations and procedures in patients without previous history of cytopenias, or altered renal or liver function tests: neutropenia (absolute neutrophil count <500 cells/microliter); thrombocytopenia (platelets <10,000/microliter); creatinine >2.5 mg/dL; aspartate transaminase or alanine transaminase >=5(SqrRoot) upper limit of normal. Inability to reliably keep research appointments and/or adhere to research procedures. Any condition that, in the opinion of the investigator, contraindicates participation in this study.  Additional Exclusion Criteria for Healthy Biological Relatives  Has HPV-related disease that may indicate enrollment as an affected participant rather than as a healthy biological relative.  Co-enrollment guidelines: Participants may be co-enrolled in other studies; however, study staff should be notified of co-enrollment.